This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bartels, C. Articles by Ehrenreich, H. Search for Related Content Social Bookmarking                   What's this?

Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis

Division of Clinical Neuroscience, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany

Kira Späte

Division of Clinical Neuroscience, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany

Henning Krampe

Division of Clinical Neuroscience, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany

Hannelore Ehrenreich

Division of Clinical Neuroscience, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany, ehrenreich{at}em.mpg.de

Treatment of multiple sclerosis (MS) is still unsatisfactory and essentially non-existing for the progressive course of the disease. Recombinant human erythropoietin (EPO) may be a promising neuroprotective/neuroregenerative treatment of MS. In the nervous system, EPO acts anti-apoptotic, antioxidative, anti-inflammatory, neurotrophic and plasticity-modulating. Beneficial effects have been shown in animal models of various neurological and psychiatric diseases, including different models of experimental autoimmune encephalomyelitis. EPO is also effective in human brain disease, as shown in double-blind placebo-controlled clinical studies on ischemic stroke and chronic schizophrenia. An exploratory study on chronic progressive MS yielded lasting improvement in motor and cognitive performance upon high-dose long-term EPO treatment.

Key Words: hematopoietic growth factor • chronic progressive multiple sclerosis (MS) • motor function • cognition • experimental autoimmune encephalomyelitis (EAE) • clinical trial • neurodegeneration • erythropoietin receptor (EPOR)

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 3, 193-206 (2008)
DOI: 10.1177/1756285608098422


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?